论文部分内容阅读
目的探讨131I标记抗CEA单抗在裸鼠人结肠癌肝转移模型的体内分布及其抑制肝转移的作用。方法在建立裸鼠人结肠腺癌肝转移模型的基础上 ,用131I标记抗CEA单抗COL 1 ,注射荷瘤裸鼠 ,观察 131I标记抗CEA单抗在荷瘤裸鼠体内分布及抑制肝转移的作用。结果体外标记抗体特异性结合率为59.9 %。在注射131I标记COL 1后24～96h肝转移灶内均有特异性放射性浓聚 ,96h瘤/肝比值为4.21。给予非特异性的131I NMIgG后 ,肝转移灶未见放射性浓聚 ,而呈全身均匀分布。131 Ⅰ COL 1治疗后3周 ,肝转移灶内癌组织可见大片坏死 ,血清CEA水平显著下降 ,肝转移灶数目及大小的抑制率分别为36.8 %和41.7%。结论131I 抗CEA单抗对防治结肠癌肝转移有潜在的临床应用前景。
Objective To investigate the distribution of 131I-labeled anti-CEA monoclonal antibody in human colon cancer liver metastasis model and its role in inhibiting hepatic metastasis. Methods Based on the establishment of human colonic adenocarcinoma liver metastasis model in nude mice, 131I-labeled anti-CEA monoclonal antibody COL 1 was used to inject tumor-bearing nude mice to observe the distribution of 131I-labeled anti-CEA monoclonal antibody in nude mice and inhibit liver metastasis. The role. Results The specific binding rate of in vitro labeled antibodies was 59.9%. After the injection of 131I-labeled COL 1, 24 to 96 h after the injection of COL 1, there were specific radioactive concentrations in the liver metastases, and the 96-h tumor-to-liver ratio was 4.21. After non-specific 131I NMIgG was administered, there was no radioactivity concentration in the liver metastases, but it was uniformly distributed throughout the body. Three weeks after 131 I COL 1 treatment, massive necrosis was observed in the liver metastases, serum CEA levels were significantly decreased, and the inhibition rates of the number and size of liver metastases were 36.8 % and 41.7%, respectively. Conclusion 131I anti-CEA monoclonal antibody may have potential clinical application in the prevention and treatment of liver metastasis of colon cancer.